Evidence map›Paper›PMID 37932689›Full record

SynthesisBMC cancer2023

Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.

Lanpeng Lu, Chaohu Chen, Hui Cheng, Hui Ding, Junqiang Tian, Hanzhang Wang, Zhiping Wang

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Lanpeng Lu *Institute of Urology, Lanzhou University Second Hospital, Lanzhou, China.
Chaohu Chen *Institute of Urology, Lanzhou University Second Hospital, Lanzhou, China.
Hui ChengInstitute of Urology, Lanzhou University Second Hospital, Lanzhou, China.
Hui DingInstitute of Urology, Lanzhou University Second Hospital, Lanzhou, China.
Junqiang TianInstitute of Urology, Lanzhou University Second Hospital, Lanzhou, China.
Hanzhang WangDepartment of Pathology and Laboratory Medicine, UConn Health Farmington, Farmington, CT, USA.
Zhiping WangInstitute of Urology, Lanzhou University Second Hospital, Lanzhou, China. wangzplzu@163.com.
Lanzhou University Second Hospital · CNLanzhou University · CNUConn Health · US

Funding

National Natural Science Foundation of China grant no. 82060459the Gansu Health Industry Research Program grant no. GSWSKY2021-014
6 · The paper itself

Abstract

backgroundIn muscle-invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) combined with radical cystectomy (RC) is critical in reducing disease recurrence, with GC (gemcitabine and cisplatin) being one of the most commonly used NACs. Different GC schedules have been used, but the best neoadjuvant regimen is still unknown. The clinical outcomes of 3 and 4 cycles of neoadjuvant GC are compared in this systematic review and meta-analysis to determine which is best for patients with MIBC.

methodsWe searched PubMed, Embase, Web of Science, Cochrane Library, CBM, CNKI, WAN FANG DATA, and meeting abstracts to identify relevant studies up to March 2023. Studies that compared 3 and 4 cycles of neoadjuvant GC for MIBC were included. The primary outcomes were pCR, pDS, OS, and CSS. The secondary outcome was recurrence and SAEs.

resultsA total of 3 studies, with 1091 patients, were included in the final analysis. Patients that received 4 cycles of GC had a higher pCR (OR = 0.66; 95% CI, 0.50-0.87; p = 0.003) and pDS (OR = 0.63; 95% CI, 0.48-0.84; p = 0.002) than those who received 3 cycles. Regarding recurrence rate (OR = 1.23; 95% CI, 0.91-1.65; p = 0.18), there were no appreciable differences between the 3 and 4 cycles of GC. Survival parameters such as OS (HR, 1.35; 95% CI, 0.86-2.12; p = 0.19) and CSS (HR, 1.06; 95% CI, 0.82-1.38; p = 0.20) were similar. Only one trial reported on the outcomes of SAEs. And there were no statistically significant differences in thrombocytopenia, infection rate, neutropenic fever, anemia, or decreased renal function between patients. The neutropenia of patients was statistically different (OR = 0.72; 95% CI, 0.52-0.99; p = 0.04).

conclusionThe 4-cycle GC regimen was superior to the 3-cycle regimen in only the pCR and pDS results. Survival and recurrence rates were similar between the two regimens. In both treatment regimes, the toxicity profile was manageable. However, due to the inherent drawbacks of retrospective research, this should be regarded with caution.

Indexed as

CisplatinUrinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCystectomyGemcitabineHumansMusclesNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalRetrospective StudiesCisplatinGemcitabineBladder cancerCisplatinGemcitabineNeoadjuvant chemotherapy

Identifiers

PMID37932689
PMCPMC10626748
OpenAlexW4388413425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.